Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients
© Román-Pérez et al.; licensee BioMed Central Ltd. 2012
Received: 22 June 2011
Accepted: 19 March 2012
Published: 19 March 2012
A gene expression signature indicative of activated wound responses is common to more than 90% of non-neoplastic tissues adjacent to breast cancer, but these tissues also exhibit substantial heterogeneity. We hypothesized that gene expression subtypes of breast cancer microenvironment can be defined and that these microenvironment subtypes have clinical relevance.
Gene expression was evaluated in 72 patient-derived breast tissue samples adjacent to invasive breast cancer or ductal carcinoma in situ. Unsupervised clustering identified two distinct gene expression subgroups that differed in expression of genes involved in activation of fibrosis, cellular movement, cell adhesion and cell-cell contact. We evaluated the prognostic relevance of extratumoral subtype (comparing the Active group, defined by high expression of fibrosis and cellular movement genes, to the Inactive group, defined by high expression of claudins and other cellular adhesion and cell-cell contact genes) using clinical data. To establish the biological characteristics of these subtypes, gene expression profiles were compared against published and novel tumor and tumor stroma-derived signatures (Twist-related protein 1 (TWIST1) overexpression, transforming growth factor beta (TGF-β)-induced fibroblast activation, breast fibrosis, claudin-low tumor subtype and estrogen response). Histological and immunohistochemical analyses of tissues representing each microenvironment subtype were performed to evaluate protein expression and compositional differences between microenvironment subtypes.
Extratumoral Active versus Inactive subtypes were not significantly associated with overall survival among all patients (hazard ratio (HR) = 1.4, 95% CI 0.6 to 2.8, P = 0.337), but there was a strong association with overall survival among estrogen receptor (ER) positive patients (HR = 2.5, 95% CI 0.9 to 6.7, P = 0.062) and hormone-treated patients (HR = 2.6, 95% CI 1.0 to 7.0, P = 0.045). The Active subtype of breast microenvironment is correlated with TWIST-overexpression signatures and shares features of claudin-low breast cancers. The Active subtype was also associated with expression of TGF-β induced fibroblast activation signatures, but there was no significant association between Active/Inactive microenvironment and desmoid type fibrosis or estrogen response gene expression signatures. Consistent with the RNA expression profiles, Active cancer-adjacent tissues exhibited higher density of TWIST nuclear staining, predominantly in epithelium, and no evidence of increased fibrosis.
These results document the presence of two distinct subtypes of microenvironment, with Active versus Inactive cancer-adjacent extratumoral microenvironment influencing the aggressiveness and outcome of ER-positive human breast cancers.
Gene expression analysis of tissue adjacent to invasive breast cancer and ductal carcinoma in situ has suggested that intratumoral stromal responses contribute to disease progression. Finak et al.  showed that elevated expression of stroma-derived immune mediators in tumor tissue predicted relapse. Chang et al. reported a signature of fibroblast response  and Beck et al. reported fibromatosis and macrophage-associated signatures, each with prognostic value [3, 4]. Stromal responses are activated at early stages in carcinogenesis, even in the absence of invasion , leading to speculation that "for acquisition of the invasive phenotype, the stroma is dominant over the epithelium" . We recently reported an in vivo wound response signature derived from tissue adjacent to breast cancer, which when expressed in tumors, predicts relapse and overall survival . The vast majority of studies evaluating stroma-derived signatures [1–5, 8–11] have focused on intratumoral stromal expression rather than extratumoral expression.
Growing evidence suggests that extratumoral microenvironment may play a role in cancer progression. Chen et al. showed that some cancer patients have gene expression patterns in their adjacent non-neoplastic tissue that are similar to invasive breast cancer signatures, and that these signatures may predict progression of early premalignant lesions . Graham et al. also found that gene expression in normal epithelium of ER positive and ER negative breast cancers echoes the ER status of the adjacent tumors . These observations suggest that the stroma and/or epithelium adjacent to tumors may harbor changes, referred to as field effects , and that these changes may be of prognostic value. However, an investigation of genomic heterogeneity in the extratumoral microenvironment, independent of effects caused by adjacent tumor characteristics, has not been reported. Identification of gene expression subtypes in the extratumoral microenvironment may provide important insights into how stromal response alters the progression of disease.
To evaluate the hypothesis that extratumoral microenvironment influences disease progression, we used cancer-adjacent non-neoplastic tissue from 72 invasive breast cancer and ductal carcinoma in situ cases to identify distinct gene expression subtypes in extratumoral tissue. Biological features of these subtypes were defined by comparison with established and novel gene expression signatures and by performing histological and immunohistochemical analyses. The novel microenvironment subtypes identified were also evaluated for associations with overall survival. Our data suggest two biologically distinct subtypes of extratumoral microenvironment with distinct biological features and clinical outcomes.
Materials and methods
Patients were women undergoing mastectomy at University of North Carolina Hospitals in Chapel Hill, NC. All patients enrolled voluntarily under Institutional Review Board-approved protocols. For histologically normal tissue adjacent to breast cancer or ductal carcinoma in situ, a pathologist from the Lineberger Comprehensive Cancer Center's Tissue Procurement Facility at the University of North Carolina in Chapel Hill confirmed that a mirror specimen adjacent to that used for RNA isolation was histologically benign.
Patients with invasive cancers (n = 68) and ductal carcinoma in situ (DCIS) (n = 4) were considered. Patients receiving neoadjuvant therapy were excluded. ER-positive patients were identified by pathologic report and endocrine-treated patients were defined as cancer patients whose medical records reflect that they received anti-estrogen therapy, such as tamoxifen or aromatase inhibitors. Median follow-up time for the 72 patients was 39 months. All tissues were handled by snap freezing immediately after surgery. RNA was isolated using established protocols as described previously .
To evaluate intra-individual variation in the signatures we identified, we used duplicate specimen samples from the same individuals. For these analyses, biospecimens included five pairs of cancer-adjacent tissue pairs from the University of North Carolina Hospitals in Chapel Hill, NC and five pairs from a study conducted by the National Cancer Institute in Warsaw and Lodz, Poland . For all 10 pairs, both peritumoral (< 2 cm) and remote (2+ cm) tissues were sampled.
Cell lines and reagents for generating TWIST and TGFβ signatures
To identify a gene expression profile associated with TWIST overexpression, the non-tumorigenic immortalized human mammary epithelial cells (HMLE) and the HMLE cells stably expressing the transcription factor TWIST1 (HMLE-TWIST)  were cultured in HuMEC media with HuMEC Supplement and Bovine Pituitary Extract (GIBCO, Carlsbad CA, USA). HMLE-TWIST cells were harvested after 48 h in culture (at 80% confluence) and compared with HMLE cells harvested under an identical protocol. To identify a signature of fibroblast activation by transforming growth factor beta (TGF-β), hTERT-immortalized fibroblasts from reduction mammoplasty patients (RMF)  (maintained as described previously ), were treated with 50 pg TGF-β1 (PeproTech, Rockyhill, NJ, USA) for 48 h. TGF-β1 was reconstituted in 10 mM Citric Acid and 2 mg/mL albumin in PBS, with supplemented media replaced every 24 h. Gene expression profiles of TGFβ-treated RMF cells were compared to those in untreated RMFs.
Microarrays were two-color Agilent 4X44k G4112F arrays (Agilent, Santa Clara, CA, USA) or custom 244 k human arrays (Agilent G4502A). The probe set common to both platforms was used for all analyses as previously described . Cy3-labeled reference was produced from total RNA from Stratagene Universal Human Reference (spiked with 1:1,000 with MCF-7 RNA and 1:1,000 with ME16C RNA to increase expression of breast cancer genes) following amplification with Agilent Quick Amp labeling kit following the manufacturer's protocol with minor modifications as described in Hu et al. . The identical protocol was applied to Cy5-label total RNA from cell lines and cancer-adjacent tissue. Data are publicly available through the Gene Expression Omnibus (GSE31589).
All data were loaded to the UNC Microarray Database for normalization and filtering. Only probes with signal intensity greater than 10 dpi in both channels were included. Data were lowess normalized, probes with at least 80% good data were selected, and missing data were imputed using k-nearest neighbors imputation with k = 10. To identify subtypes of microenvironment, we selected probes with an inter-quartile range (IQR) of at least 0.8. This probe set was used to perform unsupervised clustering of cancer-adjacent tissues (Cluster 3.0). Functional analysis of gene clusters in the unsupervised cluster was performed to identify significant functions with P-values less than 0.05 (using Ingenuity Pathway Analysis (IPA), with Benjamini-Hochberg multiple testing correction).
Associations between extratumoral microenvironment subtypes and biologically-defined gene expression signatures
To characterize the biological phenotypes of the extratumoral subtypes, gene expression in each sample was compared to existing and novel gene expression signatures. TWIST1-related signatures reflecting cellular de-differentiation and activated stroma were identified via two-class unpaired Significance Analysis of Microarrays (SAM)  with a false discovery rate (FDR) < 0.01 comparing HMLE-TWIST with parental HMLE cell line (vector only) (Cell lines used are described in ). TGF-β1-dependent responses of fibroblasts were identified using two-class unpaired SAM with FDR < 0.01 comparing treated versus sham RMFs (as described above). The median centered expression profile of each individual patient was then evaluated for correlation with these signatures by calculating Pearson correlation coefficients, using the method of Creighton et al. . Three published signatures, for desmoid-type fibrosis (DTF) , Claudin-low breast cancer  and estrogen response , were assessed the same way. Briefly, vectors corresponding to all genes in each of the five signatures were constructed, with 1 assigned to up-regulated genes and -1 assigned to down-regulated genes. A Pearson correlation coefficient was calculated for this standard vector versus the vector of median centered gene expression for each patient. Patients were classified as positive for a given signature if the Pearson correlation coefficient was greater than zero, and negative if the coefficient was less than zero.
After evaluating the 72 patient sample set as described, additional samples were microarrayed to evaluate prevalence of Active subtype as a function of distance to tumor. For each of 10 patients, 2 samples (one peritumoral and one remote) were analyzed by microarray and the 20-sample set was median-centered. Each sample was classified as Active or Inactive using the Pearson correlation coefficient for median-centered expression of that sample versus the vector of up (1) and down (-1) genes in the Active patients from the 72 patient set. Patients with a positive Pearson correlation coefficient were classified as Active (others were Inactive).
Associations between cluster group (Active versus Inactive) and overall survival were evaluated using Kaplan-Meier and Cox-Proportional Hazards analyses in R 2.11.0 (survival package). Univariate Cox models were used to estimate the hazard ratio (HR) and 95% CI. Hazard Ratios did not change substantially with exclusion of the one DCIS patient in this dataset. Relapse-free survival data were incomplete for a large number of patients and were underpowered in this dataset, but survival trends similar to those for overall survival were observed (data not shown).
Formalin fixed mirror samples of non-neoplastic tissue adjacent to breast cancer were paraffin embedded and assayed by IHC to compare markers across the 72 Active and Inactive patients and in 5 pairs of peritumoral and remote specimens collected at UNC (where paraffin was available). Five micrometer paraffin sections were obtained, deparaffinized, hydrated, and antigen retrieval (HIER) was performed using Dako Target Retrieval Solution S1699(Dako, Glostrup Denmark). Sections were washed in 0.05 M Tris buffer pH 7.6 and treated with 3.0% hydrogen peroxide in dH20 for 10 minutes to reduced endogenous peroxidase. Sections were blocked in Dako protein serum free solution (X0909) for 30 minutes and incubated overnight at 4°C with antisera against TWIST1 (Abcam, ab50887, Cambridge, UK)) diluted 1:200 in Dako antibody diluent (S0809). TWIST1 staining was revealed through the use of a biotinylated secondary (Jackson ImmunoResearch 115-065-166, Reston VA, USA), ABC complex (Standard Elite Vector Laboratories, PK6100, Burlingame, CA, USA) and reacted in diaminobenzidine (Invitrogen DAB Substrate Kit 00-2014, Carlbad, CA, USA). Subsequent hematoxylin or Masson's trichrome counterstaining was performed, slides were dehydrated, cleared in xylene and DPX (BDH 360294H) and cover-slipped for light microscopy at 10X. All slides were scanned using Aperio ScanScope CS and analyzed with Aperio Image Scope V220.127.116.115 (Vista, CA, USA) using the nuclear analysis algorithm Nuclear V9. TWIST-positive (2+ or 3+) nuclear counts per unit area of epithelium and per unit area of stroma were calculated.
Identification of distinct extratumoral microenvironment subtypes adjacent to breast cancer
Clinical characteristics of 72 patients evaluated for extratumoral gene expression subtypes
Active, N (%)
Inactive, N (%)
Breast Cancer Subtype
Tumor size (cm)
0 to 2
2.1 to 4
Biological relevance of microenvironment subtypes
Pathway analysis of enriched ontological categories, major gene clusters demarcated in Figure 1
Highly expressed in Active
Movement of cells
Homing of cells
Chemotaxis of cells
Infiltration of cells
Infiltration by neutrophils
Recruitment of macrophages
Connective Tissue Disorders
Connective tissue disorder
Organismal Injury and Abnormalities
Highly expressed in Inactive
Cell-to-Cell Signaling and Interaction
Adhesion of cells
Formation of cell-cell contacts
Formation of tight junctions
Formation of intercellular junctions
Differentiation of epithelial cells
Maturation of epithelial cells
Differentiation of epithelial tissue
Morphogenesis of epithelial tissue
The aggregation of biological behaviors observed in the Active group, as well as some of the individual gene expression changes, represented processes associated with activated stroma or active dedifferentiation/epithelial-to-mesenchymal transition (EMT). Because extratumoral microenvironments show activation of wound response gene expression , and because EMT occurs normally during wound healing  and in cancer , we performed additional analyses and experiments to evaluate the hypothesis that EMT-like signatures distinguished these two clusters. EMT is a process that alters the polarity of epithelial cells and reshapes them for movement. TWIST1, TWIST2 and ZEB2 are transcription factors that bind to E-boxes within the CDH1 promoter, suppressing transcription and ultimately down-regulating E-cadherin protein [27, 28]. Loss of E-cadherin is a key step in the dedifferentiation of epithelial cells to a mesenchymal phenotype . Simultaneously, there is a loss of cell-cell contact proteins, such as claudins, and gain of mesenchymal markers, such as vimentin and S100A4 (also known as fibroblast-specific protein 1, FSP1) [29, 30]. Additional file 3: Figure S1 visualizes the expression of the markers listed above and other established markers associated with a dedifferentiated phenotype, and demonstrates higher expression (relative to median) of TWIST1, TWIST2 and ZEB1 genes across samples in the Active Cluster. We also observed the same pattern of expression for the intermediate filament protein vimentin, the cytoskeletal protein S100A4 and the receptor tyrosine kinase DDR2. On the other hand, we found lower expression of tight junction associated proteins claudins 3, 4, 7, occludin and the calcium dependent cell-to-cell adhesion protein E-cadherin in the Active cluster.
Correlations of cancer-adjacent gene expression with biologically relevant signatures, by microenvironment subtype and tumor characteristics
Tumor subtype/tumor characteristics
Number of genesa
Non- Claudin low
P = 5.7e-11
P = 3.6e-12
P = 0.28
P = 7.7e-3
P = 0.086
P = 0.80
P = 0.010
Stroma-derived signatures were also considered in association with Active versus Inactive subtype. TGFβ signaling in the microenvironment has been implicated in tumor progression and is enriched in active wound healing, so we evaluated association of Active subtype with TGFβ signaling. Active samples were more likely to be positively correlated with the TGFβ signature, though the association was weaker than for TWIST and claudin-low signatures. We also evaluated correlation with desmoid-type fibrosis signature , which is associated with breast cancer progression when measured in tumors, and found no strong association between Active subtype and fibrosis. The relatively weaker association between Active subtype and each of these two stroma-derived signatures suggests that the biological characteristics of Active versus Inactive are more similar to the cellular dedifferentiation captured in the TWIST and claudin-low signatures.
In tumors, estrogen response gene expression strongly distinguishes two groups of patients and often drives progression . To ensure that the subtypes were not simply measuring estrogen responsiveness of the tumors and, thereby, acting as a surrogate for ER status of the tumors, we evaluated a published estrogen response signature . Consistent with previous reports that ER positive tumors are more likely to show high estrogen response gene expression in adjacent epithelium, the estrogen responsiveness signature was more likely to be positive in tissue adjacent to ER positive breast cancers. However, the Active and Inactive subtypes were independent of the estrogen response gene set, with no association between Active microenvironment and estrogen response gene expression. In other words, the Active patients are not defined by estrogen responsiveness.
Prevalence of subtypes as a function of distance from tumor
Spatial variation of the Active signature across a patient's tissue is an important consideration if the signature represents a candidate biomarker of prognosis among ER positives. For our unsupervised clustering in Figure 1, samples were taken peritumorally, but tissue was not sampled distant from the tumor and precise distances were not recorded. Thus, in a subset of samples, we specifically evaluated both peritumoral and remote tissue to identify whether two locations from the same patient were concordant (Additional file 4: Table S3). Interestingly, 60% of patients had concordant normal tissue signatures at both locations, while 40% of patients had Active signature in one location and not in the other, (that is, differences existed between peritumoral and remote signatures). This suggests that distance to tumor may be an important source of intraindividual variation in expression of this phenotype.
Pathways and processes that are part of normal homeostasis, such as wound healing and TGF-β signaling, become tumor promoting in the presence of initiated cells [32, 33]. While this has been proven experimentally, the role of these processes in predicting human cancer outcomes has been less well studied in observational contexts. We previously observed that wound healing signatures can be detected in more than 90% of tumor adjacent tissues , and in the current study, we demonstrate that extratumoral wound response can be of two types: Active and Inactive. Active cancer-adjacent tissue shows features of active EMT or cellular dedifferentiation and was associated with poor survival. Inactive extratumoral tissue maintains higher expression of cellular adhesion genes and shows lower expression levels of EMT-related transcription factors. Our preliminary estimate of the hazard ratio (HR) associated with Active (compared to Inactive) microenvironment was approximately 2.5, which is substantial considering that established genomic phenotypes such as p53 mutation status  and Cyclin E overexpression  have HRs near two. Acknowledging the limitations of this study, which included heterogeneously treated patients of various stages, the magnitude of this preliminary effect estimate suggests that the association merits further investigation for clinical relevance and lends credence to the influence of tumor microenvironment on breast cancer outcome.
The clinical relevance of our gene expression subtypes appeared, in our study, to be restricted to ER-positive patients. It is common for tumor-derived gene expression signatures to have prognostic value only among ER-positive tumors, which may be attributable to relatively uniform, poor survival among ER-negative patients. A recent paper simultaneously reviewed multiple gene expression signatures and showed that very few tumor signatures had value in predicting ER-negative breast cancer survival . However, it may also be the case that there are specific biological interactions between ER-positive tumors and their microenvironments. For example, TGF-β is a well-established paracrine mediator of breast cancer aggressiveness [36, 37], and consistent with our findings, TGF-β signatures are prognostic solely among ER-positive cancers . This example is particularly relevant given that Active microenvironments are correlated with a TGF-β signature.
Increased TGF-β signaling along with other biological characteristics of the Active microenvironment subtype suggested dedifferentiation or EMT-like gene expression, which may seem surprising given that EMT is a developmental program. However, EMT is known to be activated in normal, adult tissues undergoing wound healing (referred to as type 2 EMT, in contrast to type 1 EMT that occurs during development) . In tumors and cancer cells, EMT-associated expression has been observed [39–41] (referred to as type 3 EMT), and has recently been linked with the claudin-low subtype and with resistance to therapy [21, 23, 26, 42]. In our study, we observed that claudin-low gene expression features are more common (more than twice as likely to occur) in cancer-adjacent tissues than in breast tumors, and occur independent of whether the adjacent tumor is claudin-low. In fact, claudin-low gene expression in the adjacent tissue appears to be independent of tumor subtype altogether. This suggests that the Active signature may be an endogenous response, dependent upon patient biology and not tumor biology. It also appears that the signature can occur early in disease pathogenesis, being present in some DCIS patients in the current study.
A recent study has suggested that claudin-low features may also occur (though much less frequently) in normal tissues from non-diseased women . In that study, claudin-low features were associated with high risk of breast cancer. Future studies should assess whether the prevalence of this subtype differs according to disease progression (DCIS versus Invasive), or other patient characteristics, such as age, smoking history or race. In one study of esophageal cancers, it has been hypothesized that EMT could be artificially induced in surgery , consistent with the idea that EMT is induced during wounding. However, tumors displaying this signature were exposed to ischemic conditions for at least four hours. In collections at UNC, more than 95% of specimens are snap frozen within two hours of devascularization, with the majority snap frozen in under an hour. Thus induction of ischemic conditions is unlikely to explain our observation of EMT-like gene expression.
In support of an exogenous or tumor-specific induction of EMT-like gene expression, EMT marker expression has been previously reported as a highly localized response to cancer progression. Trujillo et al.  observed high expression of SNAIL1 and TGFβ in the breast epithelium adjacent to tumors. Interestingly, across the five patients evaluated in that study, these markers were most highly expressed in the peritumoral region (< 1 cm) and expression was much lower at a distance of 5 cm from the tumor margin. In our analyses, many pairs of peritumoral and remote tissue had pervasive expression of an EMT-like signature, both near (< 2 cm) and remote from the tumor (> 2 cm). Differences between the number of markers (hundreds of genes versus few markers) and differences in the sensitivity of RNA-based and protein-based analyses may account for differences between our study and the report by Trujillo et al. However, future work should continue to evaluate the role of distance from tumor in modifying these biological processes. If there is a wide geographic range of the tumor-effects on adjacent tissue, this has potential implications for surgery strategies. One might speculate that patients for whom a widespread gene expression alteration is present might benefit from mastectomy. If a promoting wound healing signature or Active signature persists in the lumpectomy bed, it raises the question of whether this could account for the higher rate of recurrences in this region after breast conserving therapy. If this hypothesis is to be advanced, it will be important to evaluate whether Active/Inactive signatures persists after breast conserving therapy.
Other studies of stroma-derived signatures have supported both exogenous and endogenous origins for stromal response . Whether the signature is tumor-dependent or a host factor varies signature by signature. In our findings, estrogen response signatures in extratumoral tissue were correlated with tumor ER status. However, neither the tumor ER status nor the estrogen responsiveness of the adjacent tissue were correlated with the extratumoral subtypes we identified, suggesting that the extratumoral phenotypes are not driven by hormonal exposures or endogenous hormone response. These results are important because breast tumor biology is so strongly driven by estrogen response and because previous reports have shown that estrogen positive tumor features are reflected in the adjacent normal tissue of these patients . However, while our Active and Inactive subtypes are independent of hormone receptor status of the adjacent tumor, we did recapitulate the finding of Graham et al.  that extratumoral estrogen responsiveness mirrors the ER expression phenotype of the adjacent tissue, despite the fact that we did not micro-dissect the epithelium from the stroma. Thus, we are able to report that even signatures such as estrogen responsiveness are detectable in whole (not micro-dissected) tissue. The use of whole tissue facilitates microarray analysis of a much larger number of samples (more than 90 in the current study) facilitated the assessment of clinical associations and inter-and intra-individual variation that would not have been possible with smaller sample sizes that have been used in micro-dissection studies [1, 13].
The higher prevalence of Active subtype in our study of women with DCIS and cancer (compared to the study of non-diseased high risk patients) suggests that either the signature is associated with risk or that initial activation of the signature requires the presence of tumor or another early benign lesion . Further research to determine temporality and distinguish risk and response is needed. It will also be important to determine whether there are some extratumoral signatures that are dictated by tumor characteristics, to fully explore the role of the extratumoral tissue in disease progression. For example, grade is known to induce widespread stromal alterations, but the specific molecular signatures associated with high grade tumors are not well studied. Likewise, extratumoral microenvironments that are common to basal-like breast cancers and could account for higher risk of loco-regional recurrence could provide novel insights about the biology of basal-like breast cancer progression.
We have explored novel subtypes of extratumoral microenvironment that appear to be independent of breast cancer subtype and that may have prognostic value. We have shown that these subtypes have distinct biological characteristics that may determine their clinical impact. While the extratumoral subtypes we identified were not dependent on tumor characteristics, we have confirmed the findings of others that some extratumoral characteristics vary according to the ER-status of the adjacent tumor. These results demonstrate that studying the cancer-adjacent tissue can provide novel biological and clinically-relevant insights about breast cancer progression.
ductal carcinoma in situ
false discovery rate
human mammary epithelial cells
Ingenuity Pathway Analysis
reduction mammoplasty fibroblast
Significance Analysis of Microarrays
transforming growth factor beta.
This project was supported by grants from the National Cancer Institute and National Institutes of Environmental Health Sciences (U01-ES019472, R01-CA138255), a Breast SPORE (P50CA058223) Career Development Award to M.A.T., a grant from the Avon Foundation, and the University Cancer Research Fund at the University of North Carolina. P.C-H is a Howard Hughes Medical Institute (HHMI) Med into Grad Scholar supported in part by a grant to the University of North Carolina at Chapel Hill from HHMI through the Med into Grad Initiative. S.A.M. laboratory is supported by a grant from National Institute of Cancer (R01 CA155243). We are grateful to Jonine Figueroa, Mark Sherman and Gretchen Gierach at the National Cancer Institute for contributing samples from the Polish Women's Breast Cancer study and for helpful comments on this work and to Amy Drobish for assistance with medical records abstraction for patient clinical samples.
- Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008, 14: 518-527. 10.1038/nm1764.View ArticlePubMedGoogle Scholar
- Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2: E7-10.1371/journal.pbio.0020007.View ArticlePubMedPubMed CentralGoogle Scholar
- Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB: The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res. 2009, 15: 778-787. 10.1158/1078-0432.CCR-08-1283.View ArticlePubMedPubMed CentralGoogle Scholar
- Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB: The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest. 2008, 88: 591-601. 10.1038/labinvest.2008.31.View ArticlePubMedPubMed CentralGoogle Scholar
- Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC: Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009, 11: R7-10.1186/bcr2222.View ArticlePubMedPubMed CentralGoogle Scholar
- Schedin P, Borges V: Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer. Breast Cancer Res. 2009, 11: 102-10.1186/bcr2235.View ArticlePubMedPubMed CentralGoogle Scholar
- Troester MA, Lee MH, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR, Perou CM, Jerry DJ, Schneider SS: Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res. 2009, 15: 7020-7028. 10.1158/1078-0432.CCR-09-1126.View ArticlePubMedPubMed CentralGoogle Scholar
- Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB: Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat. 2009, 123: 397-404.View ArticlePubMedPubMed CentralGoogle Scholar
- Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004, 6: 17-32. 10.1016/j.ccr.2004.06.010.View ArticlePubMedGoogle Scholar
- Cichon M, Degnim A, Visscher D, Radisky D: Microenvironmental Influences that Drive Progression from Benign Breast Disease to Invasive Breast Cancer. Journal of Mammary Gland Biology and Neoplasia. 2010, 15: 389-397. 10.1007/s10911-010-9195-8.View ArticlePubMedPubMed CentralGoogle Scholar
- de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE: Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat. 2011, 125: 687-696. 10.1007/s10549-010-0855-6.View ArticlePubMedGoogle Scholar
- Chen DT, Nasir A, Venkataramu C, Fulp W, Gruidl M, Yeatman T: Evaluation of malignancy-risk gene signature in breast cancer patients. Breast Cancer Res Treat. 2009, 120: 25-34.View ArticlePubMedPubMed CentralGoogle Scholar
- Graham K, Ge X, de Las Morenas A, Tripathi A, Rosenberg CL: Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res. 17: 236-246.
- Heaphy CM, Griffith JK, Bisoffi M: Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat. 2009, 118: 229-239. 10.1007/s10549-009-0504-0.View ArticlePubMedGoogle Scholar
- Garcia-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Bardin-Mikolajczak A, Struewing JP: Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet. 2006, 119: 376-388. 10.1007/s00439-006-0135-z.View ArticlePubMedGoogle Scholar
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.View ArticlePubMedPubMed CentralGoogle Scholar
- Proia DA, Kuperwasser C: Reconstruction of human mammary tissues in a mouse model. Nat Protoc. 2006, 1: 206-214. 10.1038/nprot.2006.31.View ArticlePubMedGoogle Scholar
- Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, Perou CM, Troester MA: Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol Cancer Res. 9: 3-13.
- Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006, 7: 96-10.1186/1471-2164-7-96.View ArticlePubMedPubMed CentralGoogle Scholar
- Tusher V, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001, 98: 5116-5121. 10.1073/pnas.091062498.View ArticlePubMedPubMed CentralGoogle Scholar
- Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA: Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA. 107: 15449-15454.
- Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV: Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008, 26: 4078-4085. 10.1200/JCO.2007.13.4429.View ArticlePubMedPubMed CentralGoogle Scholar
- Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research. 2010, 12: R68-10.1186/bcr2635.View ArticlePubMedPubMed CentralGoogle Scholar
- Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006, 24: 1656-1664. 10.1200/JCO.2005.03.2755.View ArticlePubMedGoogle Scholar
- Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, Perou CM: Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. 4: 3-
- Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 2009, 119: 1420-1428. 10.1172/JCI39104.View ArticlePubMedPubMed CentralGoogle Scholar
- Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001, 7: 1267-1278. 10.1016/S1097-2765(01)00260-X.View ArticlePubMedGoogle Scholar
- Vesuna F, van Diest P, Chen JH, Raman V: Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008, 367: 235-241. 10.1016/j.bbrc.2007.11.151.View ArticlePubMedGoogle Scholar
- Okada H, Danoff TM, Kalluri R, Neilson EG: Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol. 1997, 273: F563-574.PubMedGoogle Scholar
- Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG: Identification and characterization of a fibroblast marker: FSP1. J Cell Biol. 1995, 130: 393-405. 10.1083/jcb.130.2.393.View ArticlePubMedGoogle Scholar
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.View ArticlePubMedGoogle Scholar
- Bissell MJ, Hines WC: Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 17: 320-329.
- Sieweke M, Thompson N, Sporn M, Bissell M: Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science. 1990, 248: 1656-1660. 10.1126/science.2163544.View ArticlePubMedGoogle Scholar
- Rossner P, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M, Kalra TS, Gaudet MM, Teitelbaum SL, Neugut AI, Santella RM: Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med. 2009, 13: 3847-3857. 10.1111/j.1582-4934.2008.00553.x.View ArticlePubMedGoogle Scholar
- Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS: Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002, 347: 1566-1575. 10.1056/NEJMoa021153.View ArticlePubMedGoogle Scholar
- Barcellos-Hoff MH, Akhurst RJ: Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res. 2009, 11: 202-10.1186/bcr2224.View ArticlePubMedPubMed CentralGoogle Scholar
- Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL: TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004, 303: 848-851. 10.1126/science.1090922.View ArticlePubMedGoogle Scholar
- Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL: Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest. 2009, 119: 1571-1582. 10.1172/JCI37480.View ArticlePubMedPubMed CentralGoogle Scholar
- Foubert E, De Craene B, Berx G: Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res. 2010, 12: 206-10.1186/bcr2585.View ArticlePubMedPubMed CentralGoogle Scholar
- Sehgal PB: Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells. Oncogene. 2010, 29: 2599-2600. 10.1038/onc.2010.4. author reply 2601-2593View ArticlePubMedPubMed CentralGoogle Scholar
- Tuhkanen H, Soini Y, Kosma VM, Anttila M, Sironen R, Hamalainen K, Kukkonen L, Virtanen I, Mannermaa A: Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression. BMC Cancer. 2009, 9: 289-10.1186/1471-2407-9-289.View ArticlePubMedPubMed CentralGoogle Scholar
- Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2: 442-454. 10.1038/nrc822.View ArticlePubMedGoogle Scholar
- Haakensen VD, Lingjaerde OC, Luders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Borresen-Dale AL, Helland A: Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Med Genomics. 2011, 4: 77-10.1186/1755-8794-4-77.View ArticlePubMedPubMed CentralGoogle Scholar
- Aoyagi K, Minashi K, Igaki H, Tachimori Y, Nishimura T, Hokamura N, Ashida A, Daiko H, Ochiai A, Muto M, Ohtsu A, Yoshida T, Sasaki H: Artificially induced epithelial-mesenchymal transition in surgical subjects: its implications in clinical and basic cancer research. PLoS One. 2011, 6: e18196-10.1371/journal.pone.0018196.View ArticlePubMedPubMed CentralGoogle Scholar
- Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler K, Joste N, Bisoffi M, Griffith JK: Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer. 129: 1310-1321.
- Wu JM, Beck AH, Pate LL, Witten D, Zhu SX, Montgomery KD, Allison KH, van de Rijn M, West RB: Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes. Clin Cancer Res. 17: 437-446.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.